Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder that is caused by a somatic mutation of the PIG-A gene. The biochemical consequence of PIG-A mutations is a global loss of glycosylphosphatidyl-inositol anchored proteins (GPI-AP). Two GPI-AP (CD55 and CD59) are important complement regulatory proteins, their absence explains the complement-mediated intravascular hemolysis and thrombosis and that occur in PNH patients;however, the mechanism by which PNH cells achieve clonal dominance is not completely understood. All PNH patients have been shown to harbor PIG-A mutations; however, rare PIG-A mutations can also be found in healthy control subjects;thus, the biologic relevance of PIG-A mutations in healthy controls remains to be determined. The overall objective of these studies is to study the relevance of GPI-anchor deficiency in PNH, normal, and malignant lymphohematopoietic cells. Our preliminary data demonstrates that hematopoietic cells can acquire a PNH phenotype (no cell surface GPI-AP) without PIG-A mutations. The mechanism of GPI-AP deficiency in these cells is through transcriptional silencing of genes required for GPI anchor biosynthesis. We have also established a PIGAnull CD34+ cell line with the PIG-A gene under the control of an inducible promoter. This cell line serves as a valuable model to study the mechanism of clonal dominance in PNH. Our preliminary data shows that PNH cells are relatively resistant to T cell mediatied apoptosis, and that the growth advantage of the PNH cells is amplified in the setting of an immune attack. Why PNH cells are resistant to T cell mediated killing is unclear, but our preliminary data suggest it may be related to perturbed signaling through membrane rafts and reduced ability to generate the proapoptotic second messenger, ceramide. Specifically, we will: 1) Investigate the relevance of GPI-AP deficient cells in normals. Hypothesis 1.1: GPI-AP deficiency in lymphocytes from normals can result from a novel mechanism that does not involve PICA mutations. Hypothesis 1.2: In healthy controls, a subset of HSPC in are GPI-APIo/neg, but do not harbor PIG-A mutations. 2) Study the role of GPI-anchor deficiency in cellular resistance to apoptosis. Hypothesis 2.1: GPI-APIo/neg cells are resistant to immune attack via global resistance to apoptosis. Hypothesis 2.2:GPI-anchor expression plays a role in the response of normal cells to apoptotic stimuli. Hypothesis 2.3: Lack of GPI-AP expression disrupts lipid raft signaling.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA070970-13
Application #
8212934
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2011-02-01
Project End
2013-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$289,001
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gamper, Christopher J; Takemoto, Clifford M; Chen, Allen R et al. (2016) High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. J Pediatr Hematol Oncol 38:627-635
Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79
Sharrow, Allison C; Perkins, Brandy; Collector, Michael I et al. (2016) Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy. Gynecol Oncol 142:341-8
Kim, MinJung; Tan, Yee Sun; Cheng, Wen-Chih et al. (2015) MIR144 and MIR451 regulate human erythropoiesis via RAB14. Br J Haematol 168:583-97
Candia, Julián; Cherukuri, Srujana; Guo, Yin et al. (2015) Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach. Converg Sci Phys Oncol 1:
Ma, Hayley S; Nguyen, Bao; Duffield, Amy S et al. (2014) FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 74:5206-17
Belet, Stefanie; Fieremans, Nathalie; Yuan, Xuan et al. (2014) Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality. Hum Mutat 35:350-5
Brodsky, Robert A (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804-11
Rau, Rachel; Magoon, Daniel; Greenblatt, Sarah et al. (2014) NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Exp Hematol 42:101-13.e5
Tan, Yee Sun; Kim, MinJung; Kingsbury, Tami J et al. (2014) Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia. PLoS One 9:e111777

Showing the most recent 10 out of 60 publications